Provided by Tiger Trade Technology Pte. Ltd.

Corvus Pharmaceuticals

15.25
+0.08000.53%
Post-market: 15.250.00000.00%19:43 EDT
Volume:1.21M
Turnover:18.77M
Market Cap:1.28B
PE:-28.77
High:16.09
Open:15.21
Low:15.00
Close:15.17
52wk High:26.95
52wk Low:3.02
Shares:83.77M
Float Shares:67.20M
Volume Ratio:1.87
T/O Rate:1.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5300
EPS(LYR):-0.5320
ROE:-32.60%
ROA:-38.36%
PB:20.87
PE(LYR):-28.66

Loading ...

Corvus Pharmaceuticals Shares Down 9.9% Premarket After Co Launches $150 Mln Stock Offering

THOMSON REUTERS
·
Jan 21

24H | Gold, Silver Stocks and ETFs Gain as Gold Tops $4,836; United Air Rises on Upbeat Outlook

Tiger Newspress
·
Jan 21

BRIEF-Corvus Pharmaceuticals Inc Suspends Offering Of Common Stock Shares By & Between Co & Jefferies

Reuters
·
Jan 21

Corvus Pharmaceuticals Suspends At-The-Market Equity Program

TIPRANKS
·
Jan 21

BUZZ-Corvus Pharma slips after launching $150 mln equity offering

Reuters
·
Jan 21

Corvus Pharmaceuticals Inc - No Atm Shares Sold, $100 Mln Remains Available for Sale - SEC Filing

THOMSON REUTERS
·
Jan 21

Corvus Pharmaceuticals Inc - Suspends Offering of Common Stock Shares by & Between Co & Jefferies - SEC Filing

THOMSON REUTERS
·
Jan 21

Corvus Pharmaceuticals announces $150M common stock offering

TIPRANKS
·
Jan 21

Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

THOMSON REUTERS
·
Jan 21

Corvus Pharmaceuticals price target raised to $28 from $16 at Barclays

TIPRANKS
·
Jan 21

Top Midday Gainers

MT Newswires Live
·
Jan 21

Corvus Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jan 21

Corvus Pharmaceuticals Up Over 97%, on Track for Highest Close Since October 2017 -- Data Talk

Dow Jones
·
Jan 21

Corvus Pharmaceuticals price target raised to $27 from $11 at H.C. Wainwright

TIPRANKS
·
Jan 21

Corvus Pharmaceuticals, Immunitybio, Acadia Healthcare And Other Big Stocks Moving Higher On Tuesday

Benzinga_recent_news
·
Jan 20

Corvus announces results from cohort 4 of Phase 1 trial of soquelitinib

TIPRANKS
·
Jan 20

Corvus Pharmaceuticals Reports Positive Phase 1 Results for Soquelitinib in Atopic Dermatitis

Reuters
·
Jan 20

Corvus Pharmaceuticals Inc - Plans Phase 2 Trial for Soquelitinib in Q1 2026

THOMSON REUTERS
·
Jan 20

Corvus Pharmaceuticals Announces Positive Data From Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

THOMSON REUTERS
·
Jan 20

Corvus Pharmaceuticals : Cohort 4 Data Demonstrated Positive Safety and Efficacy Results

THOMSON REUTERS
·
Jan 20